Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women

Atherosclerosis

Volumn 208, Issue 2, 2010, Pages 557-563

  Jefferis, Barbara J ^a   Whincup, Peter ^b   Welsh, Paul ^c   Wannamethee, Goya ^a   Rumley, Ann ^c   Lennon, Lucy ^a   Thomson, Andy ^a   Lawlor, Debbie ^d   Carson, Claire ^e   Ebrahim, Shah ^e   Lowe, Gordon ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cohort; Epidemiology; Inflammation; MMP 9; Myocardial infarction; Prospective; Stroke

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GELATINASE B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FAMILY HISTORY; FEMALE; FORCED EXPIRATORY VOLUME; GEOMETRY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE;

AGED; ATHEROSCLEROSIS; COHORT STUDIES; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK; RISK FACTORS; STROKE;

EID: 74749104094     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.08.018     Document Type: Article

References (24)

1. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
2. Galis Z.S., Sukhova G.K., Lark M.W., and Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
3. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
4. Wu T.C., Leu H.B., Lin W.T., et al. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest 35 (2005) 537-545
5. Cavusoglu E., Ruwende C., Chopra V., et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 151 (2006) 1101-1108
6. Eldrup N., Gronholdt M.L., Sillesen H., and Nordestgaard B.G. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 114 (2006) 1847-1854
7. Welsh P., Whincup P.H., Papacosta O., et al. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM 101 (2008) 785-791
8. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 69 (2006) 636-645
9. Yasmin, McEniery C.M., O'Shaughnessy K.M., et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 26 (2006) 1799-1805
10. Hlatky M.A., Ashley E., Quertermous T., et al. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J 154 (2007) 1043-1051
11. Kaplan R.C., Smith N.L., Zucker S., et al. Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis 201 (2008) 130-137
12. Walker M., Whincup P.H., and Shaper A.G. The British Regional Heart Study 1975-2004. Int J Epidemiol 33 (2004) 1185-1192
13. Lawlor D.A., Bedford C., Taylor M., and Ebrahim S. Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health 57 (2003) 134-140
14. Wannamethee S.G., Lowe G.D., Whincup P.H., et al. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 105 (2002) 1785-1790
15. Danesh J., Kaptoge S., Mann A.G., et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5 (2008) e78
16. Emberson J.R., Whincup P.H., Morris R.W., et al. Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study. Eur J Cardiovasc Prev Rehabil 11 (2004) 125-134
17. World Health Organization Expert Committee. Hypertension and coronary heart disease: classification and criteria for epidemiological studies. Geneva: World Health Organization; 1959. Report no.: 168.
18. Rosner B., Spiegelman D., and Willett W.C. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 136 (1992) 1400-1413
19. Sundstrom J., Evans J.C., Benjamin E.J., et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109 (2004) 2850-2856
20. Garvin P., Nilsson L., Carstensen J., et al. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS ONE 3 (2008) e1774
21. Thomas M.C., Walker M., Lennon L.T., et al. Non-attendance at re-examination 20 years after screening in the British Regional Heart Study. J Public Health Med 24 (2002) 285-291
22. Gerlach R.F., Demacq C., Jung K., and Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 40 (2007) 119-123
23. Thrailkill K., Cockrell G., Simpson P., et al. Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens. Clin Chem Lab Med 44 (2006) 503-504
24. Wu C.Y., Wu M.S., Chiang E.P., et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 13 (2007) 2054-2060